Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.88 |
| ▸ | CA2 | P00918 | 6/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69218 | 0.94 | CA1 (0.75) | CA1CA2MAPTKMT2AKDM4E | |
| Methyl 4-Methoxybenzoate SCHEMBL231243 | 0.94 | CA1 (1.00) | CA1CA2MAPTKMT2AKDM4E | |
| SCHEMBL16573856 | 0.93 | CA1 (0.75) | CA1CA2MAPTKMT2AKDM4E | |
| Methyl 4-Methoxybenzoate SCHEMBL27405603 | 0.91 | CA1 (0.95) | CA1CA2MAPTKMT2AKDM4E | |
| Methyl 4-Methoxybenzoate SCHEMBL28248974 | 0.89 | CA1 (0.91) | CA1CA2MAPTKMT2AKDM4E | |
| SCHEMBL269558 | 0.88 | CA1 (0.88) | CA1CA2MAPTKMT2AKDM4E | |
| SCHEMBL2273711 | 0.88 | CA1 (0.88) | CA1CA2MAPTKMT2AKDM4E | |
| SCHEMBL9731450 | 0.88 | CA1 (0.67) | CA1CA2MAPTKMT2AKDM4E | |
| Methyl 4-Methoxybenzoate SCHEMBL27540366 | 0.88 | CA1 (0.88) | CA1CA2MAPTKMT2AKDM4E | |
| SCHEMBL16604876 | 0.88 | CA1 (0.88) | CA1CA2MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370771-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2200985-B1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2200985-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | CA1 4254/4885CA2 1717/4885MAPT 2209/4885 |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | CA1 3785/4885CA2 265/4885MAPT 2178/4885 |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | CA1 4254/4885CA2 1717/4885MAPT 2209/4885 |
| US-11370771-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | CA1 3785/4885CA2 265/4885MAPT 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.